Kawanami, D.; Matoba, K.; Takeda, Y.; Nagai, Y.; Akamine, T.; Yokota, T.; Sango, K.; Utsunomiya, K.
SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy. Int. J. Mol. Sci. 2017, 18, 1083.
https://doi.org/10.3390/ijms18051083
AMA Style
Kawanami D, Matoba K, Takeda Y, Nagai Y, Akamine T, Yokota T, Sango K, Utsunomiya K.
SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy. International Journal of Molecular Sciences. 2017; 18(5):1083.
https://doi.org/10.3390/ijms18051083
Chicago/Turabian Style
Kawanami, Daiji, Keiichiro Matoba, Yusuke Takeda, Yosuke Nagai, Tomoyo Akamine, Tamotsu Yokota, Kazunori Sango, and Kazunori Utsunomiya.
2017. "SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy" International Journal of Molecular Sciences 18, no. 5: 1083.
https://doi.org/10.3390/ijms18051083
APA Style
Kawanami, D., Matoba, K., Takeda, Y., Nagai, Y., Akamine, T., Yokota, T., Sango, K., & Utsunomiya, K.
(2017). SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy. International Journal of Molecular Sciences, 18(5), 1083.
https://doi.org/10.3390/ijms18051083